Inflammation as a risk factor for stroke in atrial fibrillation: data from a microarray data analysis

Yingyuan Li*, Wulin Tan*, Fang Ye*, Shihong Wen, Rong Hu, Xiaoying Cai, Kebing Wang and Zhongxing Wang

Abstract
Objective: Stroke is a severe complication of atrial fibrillation (AF). We aimed to discover key genes and microRNAs related to stroke risk in patients with AF using bioinformatics analysis.

Methods: GSE66724 microarray data, including peripheral blood samples from eight patients with AF and stroke and eight patients with AF without stroke, were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between AF patients with and without stroke were identified using the GEO2R online tool. Functional enrichment analysis was performed using the DAVID database. A protein–protein interaction (PPI) network was obtained using the STRING database. MicroRNAs (miRs) targeting these DEGs were obtained from the miRNet database. A miR–DEG network was constructed using Cytoscape software.

Results: We identified 165 DEGs (141 upregulated and 24 downregulated). Enrichment analysis showed enrichment of certain inflammatory processes. The miR–DEG network revealed key genes, including MEF2A, CAND1, PELI1, and PDCD4, and microRNAs, including miR-1, miR-1-3p, miR-21, miR-21-5p, miR-192, miR-192-5p, miR-155, and miR-155-5p.

Conclusion: Dysregulation of certain genes and microRNAs involved in inflammation may be associated with a higher risk of stroke in patients with AF. Evaluating these biomarkers could improve prediction, prevention, and treatment of stroke in patients with AF.

Keywords
MicroRNAs, stroke, atrial fibrillation, computational biology, microarray analysis, MEF2A, CAND1

Date received: 9 September 2019; accepted: 1 April 2020

Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

*These authors contributed equally to this work.

Corresponding author:
Zhongxing Wang, Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Rd. 2, Yuexiu district, Guangzhou, Guangdong Province 510080, China.
Email: doctorwzx@126.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
**Introduction**

Persistent or permanent atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. AF is the second most common risk factor for ischemic stroke, the prevention of which is the main goal of treating patients with AF.\(^1\)\(^-\)\(^3\) In AF patients suffering stroke, a cardiac embolus originating from the left atrial appendage is a common cause.\(^4\)\(^,\)\(^5\) Patients with AF-related stroke seem to have a worse prognosis, such as more severe disability and greater mortality, than those with stroke in the absence of AF.\(^6\)\(^,\)\(^7\) Today, an increasing number of studies are focusing on the prevention and intervention of stroke in AF patients. One approach is to find suitable biomarkers by which to identify patients at greatest risk of stroke.

A number of traditional cardiovascular-related biomarkers have been explored to predict or clarify the risk of stroke in patients with AF. Troponin is one of these risk factors. A substudy of the RE-LY trial showed that troponin level is associated with thromboembolic events such as stroke.\(^8\) Other research has suggested that cardiac troponin high-sensitivity (cTn-hs) can be a biomarker independently associated with risk of stroke in AF.\(^9\) In contrast, a substudy of the ARISTOTLE trial suggested that plasma D-dimer, a marker of fibrin turnover, is a potential predictor of stroke, mortality, and major bleeding.\(^10\) The RE-LY substudy showed that the level of N-terminal pro b-type natriuretic peptide (NT-proBNP) is related to the risk of thromboembolic events and cardiovascular mortality.\(^8\)

Recently, new biomarkers have been reported for prediction and treatment of stroke in AF. For example, phosphodiesterase 4D may be a risk factor for AF and stroke.\(^11\) Asymmetrical dimethylarginine may be used to predict a pro-thrombotic state in AF and correlate with the risk of stroke based on the CHADS\(_2\)/CHA\(_2\)DS\(_2\)-VASc score.\(^12\) Variations in the gene encoding alanine-glyoxylate aminotransferase 2 may be involved in age-related thromboembolic complications in AF.\(^13\) New therapeutic targets have also been studied. Heat-shock protein 70-kDa induction seems to delay thrombus formation with minimal bleeding risk, which is promising for reducing the risk of stroke in AF patients.\(^14\)

In this study, we downloaded microarray data from the Gene Expression Omnibus (GEO) database and screened differentially expressed genes (DEGs) between AF patients with stroke and those without stroke. MicroRNAs, which are small non-coding RNA molecules (containing about 22 nucleotides), targeting these DEGs were also included in our analysis. We aimed to explore new mechanisms, molecular biomarkers, and potential therapeutic targets for stroke in AF patients.

**Methods**

**Microarray data**

All of the data we used were obtained from open access databases on the Internet and did not require ethical permission or patient consent to use.

We downloaded the microarray data of GSE66724 from the GEO database (http://www.ncbi.nlm.nih.gov/geo/) with its microarray platform as GPL570 ([HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array). The gene expression files were deposited by Allende et al.\(^14\) Peripheral blood was used in the microarray analysis. According to the original study,\(^14\) 16 nonvalvular AF patients were recruited, 8 of whom had suffered a cardioembolic stroke. Stroke and non-stroke patients were matched by CHAD index and sex. All patients were on anticoagulant
treatment with acenocoumarol, with an international normalized ratio (INR) between 2 and 3 at the time of blood withdrawal. AF was diagnosed by electrocardiography and lasted more than 3 months. Cardioembolic stroke was diagnosed clinically by imaging techniques (magnetic resonance imaging or X-ray computed tomography). Patients were excluded from the study if they met any of the following criteria: carotid artery lesion occluding more than 50% of the lumen vessel diameter in the side of the infarction, cancer in progress, leukocytosis (>7,000 cells/mL), leukopenia (<3,500 cells/mL), history of venous thromboembolism in the last 3 months, acute coronary syndrome, infection, autoimmune disease, or surgery. Renal failure (creatinine value more than double the normal value), oral contraceptive use, hormonal therapy, and corticoid consumption were also exclusion criteria.

**Screening DEGs**

DEGs were screened using the online tool GEO2R in the GEO database. GEO2R is an R-programming-based language for analysis of gene expression datasets by t-test or analysis of variance (ANOVA). It can help identify DEGs between two groups of samples under the same condition. In the present study, DEGs between stroke and non-stroke AF patients were screened and selected by the cutoff point of $P < 0.05$ and $|\log FC| > 0.5$, where FC is the fold change difference.

**Functional enrichment analysis**

We uploaded the selected DEGs to the Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.8 Beta (https://david-d.ncifcrf.gov/) for further analysis. The DAVID database provides useful functional annotation tools to help researchers understand the biological meaning of genes. In our study, DAVID was used to investigate Gene Ontology (GO) annotations and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to the selected DEGs. These biological processes and pathways might be associated with stroke in AF patients. $P < 0.05$ was chosen as the selection threshold.

**Protein–protein interaction analysis**

Protein–protein interaction (PPI) pairs of DEGs were obtained from Search Tool for the Retrieval of Interacting Genes (STRING, http://string-db.org/). The STRING database is an online database resource containing a collection of comprehensive information of predicted and experimental interactions of proteins. In our study, a PPI confidence score $>0.6$ was considered the threshold of significance to construct the PPI network. The generated list of PPI pairs was downloaded for further analysis.

**MicroRNAs targeting the DEGs**

The DEGs were uploaded to the database miRNet (http://www.mirnet.ca/faces/home.xhtml) to obtain microRNAs (miRs) targeting these DEGs. miRNet is an online tool with comprehensive support for statistical analysis and functional interpretation of data generated in microRNA studies. It allows researchers to build miR–target interaction networks. The generated list of miR–DEG pairs was downloaded for further analysis.

**Construction of miR–DEG network**

A miR–DEG network composed of both miR–DEG pairs and PPI pairs was constructed and visualized using Cytoscape software 3.4.0. To determine the key functional modules, module clustering analysis for the network was then performed by the
Molecular Complex Detection (MCODE)\textsuperscript{21} plugin. We set the degree cutoff value to 2 and the node score cutoff to 0.2 for the MCODE process.

**Results**

**DEG screening**

Data normalization and cross-comparability were assessed (Figure 1), and then DEGs were analyzed. A total of 165 DEGs were selected using the cutoff point of $P < 0.05$ and $|\log FC| > 0.5$, which included 141 upregulated and 24 downregulated DEGs.

**Functional enrichment analysis**

Twenty-one GO terms ($P < 0.05$) were significantly enriched by upregulated DEGs, and 29 ($P < 0.05$) were significantly enriched by downregulated DEGs. Many of these enriched terms were associated with immune or inflammatory processes, which are listed in Table 1. Only one KEGG pathway (hsa04066:HIF-1 signaling pathway) was identified by upregulated DEGs (\textit{ANGPT1}, \textit{EGLN1}, \textit{IFNGRI}) but it was not significant.

**Construction of miR–DEG network**

Taking the selected 165 DEGs into account, we identified 38 PPI pairs by STRING, and 4,739 miR–DEG pairs by miRNet. These two pairing pictures were merged and a complex miR–DEG network was generated in Cytoscape. To assess the key functional modules of this network, module clustering was then performed using the MCODE plugin of Cytoscape. Three modules were identified (Figure 2). Two DEGs, \textit{MEF2A} and \textit{PELI1}, in these modules also occurred in the GO terms enriched above, and their interacting DEGs, such as \textit{CAND1} and \textit{PDCD4}, and miRs were associated with inflammatory processes or certain cardiovascular diseases.

**Discussion**

One of the main goals when treating AF is to prevent stroke. The CHA\textsubscript{2}DS\textsubscript{2}-VASc score is a commonly used clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic AF. Risk factors in CHA\textsubscript{2}DS\textsubscript{2}-VASc score include congestive heart failure, hypertension, age $\geq$75 years, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease, age 65 to 74 years, and sex. The major treatment based on the CHA\textsubscript{2}DS\textsubscript{2}-VASc score is the use of anticoagulants to decrease the risk of stroke.\textsuperscript{22,23} However, despite careful management, some patients still suffer a stroke. In addition, anticoagulants may increase the risk of bleeding in some
| Term                                                                 | P-value  | Genes                                                                                              |
|----------------------------------------------------------------------|----------|---------------------------------------------------------------------------------------------------|
| **Upregulated**                                                      |          |                                                                                                   |
| GO:0002764–immune response-regulating signaling pathway             | 0.017683 | PELI1, MEF2A, IRS2, LAMTOR3, F2RL1, RASGEF1A, IGKV4-1, ANGPT1, RAPGEF2, FCRL5                      |
| GO:0042330–taxis                                                    | 0.031543 | ALCAM, NOV, IRS2, LAMTOR3, ST8SIA4, F2RL1, RASGEF1A, ANGPT1, RAPGEF2, EPHB1, SPP1                |
| GO:0006935–chemotaxis                                              | 0.031543 | ALCAM, NOV, IRS2, LAMTOR3, ST8SIA4, F2RL1, RASGEF1A, ANGPT1, RAPGEF2, EPHB1, SPP1                |
| GO:0038095–Fc-epsilon receptor signaling pathway                    | 0.040044 | IRS2, LAMTOR3, RASGEF1A, IGKV4-1, ANGPT1, RAPGEF2                                                |
| GO:0034141–positive regulation of toll-like receptor 3 signaling pathway | 0.04084  | PELI1, F2RL1                                                                                      |
| GO:0050776–regulation of immune response                            | 0.041524 | PELI1, MEF2A, IRS2, LAMTOR3, HLX, F2RL1, RASGEF1A, IGKV4-1, ANGPT1, RAPGEF2, FCRL5, IFNGR1       |
| **Downregulated**                                                   |          |                                                                                                   |
| GO:0002437–inflammatory response to antigenic stimulus             | 0.001872 | ELANE, HLA-DRB4, SPN                                                                              |
| GO:0050728–negative regulation of inflammatory response            | 0.006285 | ELANE, HLA-DRB4, SPN                                                                              |
| GO:0002862–negative regulation of inflammatory response to antigenic stimulus | 0.012856 | HLA-DRB4, SPN                                                                                     |
| GO:0002438–acute inflammatory response to antigenic stimulus       | 0.022107 | ELANE, SPN                                                                                         |
| GO:0002684–positive regulation of immune system process            | 0.022618 | PSMFI, ELANE, HLA-DRB4, TAB3, SPN                                                                  |
| GO:0002861–regulation of inflammatory response to antigenic stimulus | 0.023258 | HLA-DRB4, SPN                                                                                     |
| GO:0050776–regulation of immune response                            | 0.029438 | PSMFI, ELANE, HLA-DRB4, TAB3, SPN                                                                  |
| GO:0006935–immune response                                         | 0.041101 | APOBEC3B, PSMFI, ELANE, HLA-DRB4, TAB3, SPN                                                        |
| GO:0050778–positive regulation of immune response                  | 0.043136 | PSMFI, ELANE, HLA-DRB4, TAB3                                                                      |
| GO:0050727–regulation of inflammatory response                     | 0.045142 | ELANE, HLA-DRB4, SPN                                                                              |

GO, Gene Ontology; DEG, differentially expressed gene.
contraindicated patients. Therefore, new risk factors and targets of therapeutic intervention need to be identified.

Some previous studies proposed that inflammation is an independent risk factor for and contributes to the occurrence of thromboembolism and stroke in AF patients. Associations between miRNAs and certain cardiovascular diseases have also been uncovered in recent years. Zhang et al. suggested a role for miRNAs in the mechanism of inflammation in AF. McManus and Freedman suggested that platelet-derived miRNAs have important roles as biomarkers of susceptibility, prognosis, or treatment of certain cardiovascular diseases, including stroke and AF. Llombart et al. suggested that circulating miRNAs may be used in the diagnosis of cardioembolic stroke.

In the present study, based on the GSE66724 dataset from the GEO database, 165 DEGs were found between AF patients with stroke and those without stroke. Key biological processes were enriched based on these DEGs, many of which were associated with immune or inflammatory processes. We constructed three miR–DEG modules, which contained DEGs and miRNAs that were also associated with inflammation or cardiovascular diseases. This implied a mechanism of inflammation precipitating stroke in patients with AF.

Figure 2. The three functional modules. Module A involves MEF2A and CAND1, and module C involves PELI1 and PDCD4, 4 genes reported to be associated with cardiovascular disease or inflammatory processes. Red triangles represent upregulated DEGs, green triangles represent downregulated DEGs, and blue rectangles represent microRNAs. DEG, differentially expressed gene.
myocardial infarction, and arrhythmias. Calcium signaling is a central regulator of cardiomyocyte growth and function. Ikeda et al. suggested that miR-1 regulates cardiomyocyte growth responses by negatively regulating the calcium signaling components calmodulin, MEF2A, and GATA4. miR-21 has been shown to play important roles in the development of heart diseases. Its level was found to increase in fibroblasts of the failing heart, and in vivo silencing of miR-21 was shown to inhibit interstitial fibrosis and improve cardiac function in a pressure-overload cardiac disease mouse model. In addition, atrial fibrosis is important for the pathogenesis of atrial fibrillation. miR-21 was found to be over-expressed in atrial tissue from patients with AF and was proposed to play a role in the pathogenesis of atrial fibrosis. miR-192 is also upregulated in certain cardiac diseases, including heart failure after acute myocardial infarction and hypertrophic cardiomyopathy.

Pellino E3 ubiquitin protein ligase 1 (PELI1; \(P = 0.0218, \text{logFC} = 0.543\)) and programmed cell death 4 (PDCD4; \(P = 0.0138, \text{logFC} = 0.66\)) were two upregulated DEGs discovered in this study. PELI1 is involved in the toll-like receptor (TLR) and interleukin-1 signaling pathways, which are associated with inflammation. PELI1 was proposed as a microglia-specific mediator of central nervous system (CNS) inflammation. PDCD4 is a protein-coding gene. Diseases associated with PDCD4 include colorectal cancer, in which downregulation of PDCD4 was found to be associated with inflammation and certain miR pathways. In contrast, activation of PDCD4 was found in coronary microembolization-related cardiac dysfunction that could, in turn, be improved by inhibition of the PDCD4 pathway via miR-21 transfection, which sheds light upon new therapeutic targets.

The miR–DEG module C that we constructed showed that PELI1 and PDCD4 were co-regulated by miR-155 and miR-155-5p. Previous studies have indicated an intimate relationship between inflammation, innate immunity, and miR-155 expression. miR-155 is essential for the generation and function of T follicular helper (Tfh) cells through a miR-155-PELI1-c-Rel pathway. miR-155 is associated with cancer metastasis through pathways including PDCD4.

As with AF, miR-155 was found to be upregulated in left atrial appendage from nonvalvular AF patients, which indicates a role of miR-155 in electric remodeling of AF. In contrast, miR-155 polymorphism was found to be associated with the risk of ischemic stroke. miR-155 mediates inflammatory responses in ischemic cerebral tissue and other CNS neuroinflammatory disorders. More importantly, inhibition of miR-155 exerts an anti-inflammatory action and promotes recovery after stroke, indicating that miR-155 may be a potential therapeutic target.

In summary, by bioinformatic approaches, we constructed a stroke-related miR–DEG network in patients with AF. Dysregulation of certain genes and miRNAs in the network involved in inflammation may be associated with a higher risk of stroke in AF patients, which suggests that inflammation might be a potential risk factor of stroke that should be considered when assessing and treating AF patients. Certain genes, including MEF2A, CAND1, PELI1, and PDCD4, as well as miRNAs, including miR-1, miR-1-3p, miR-21, miR-21-5p, miR-192, miR-192-5p, miR-155, and miR-155-5p, were identified and might play key roles in the pathogenesis of stroke in patients with AF. Evaluation of these biomarkers could improve the prediction, prevention, and treatment of stroke in patients with this dysrhythmia. However,
further studies are necessary to verify the clinical applications of these findings.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This work was funded by grants from the National Natural Science Foundation of China (Grant no. 81601711) and Science and Technology Project of Guangzhou (Grant no. 201904010418) to Zhongxing Wang. The funding sources had no involvement in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the article for publication.

ORCID iDs
Yingyuan Li https://orcid.org/0000-0002-7160-1474
Fang Ye https://orcid.org/0000-0002-0312-2412
Zhongxing Wang https://orcid.org/0000-0003-4490-6202

References
1. Pritchett EL. Management of atrial fibrillation. *N Engl J Med* 1992; 326: 1264–1271.
2. Lip GY, Metcalfe MJ and Rae AP. Management of paroxysmal atrial fibrillation. *Q J Med* 1993; 86: 467–472.
3. Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. *Ann Intern Med* 1994; 120: 449–457.
4. Anderson DC, Kappelle LJ, Eliasziw M, et al. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. *Stroke* 2002; 33: 1963–1967.
5. Harrison MJ and Marshall J. Atrial fibrillation, TIAs and completed strokes. *Stroke* 1984; 15: 441–442.
6. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke* 1996; 27: 1760–1764.
7. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). *Stroke* 2001; 32: 392–398.
8. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. *Circulation* 2012; 125: 1605–1616.
9. Hijazi Z, Ziad H, Johan L, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart J* 2016; 37: 1582–1590.
10. Christersson C, Wallentin L, Andersson U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation—observations from the ARISTOTLE trial. *J Thromb Haemost* 2014; 12: 1401–1412.
11. Jørgensen C, Yasmeen S, Iversen HK, et al. Phosphodiesterase4D (PDE4D)–A risk factor for atrial fibrillation and stroke? *J Neurol Sci* 2015; 359: 266–274.
12. Lao MC, Liu LJ, Luo CF, et al. [Effect of asymmetrical dimethylarginine for predicting pro-thrombotic risk in atrial fibrillation]. *Zhonghua Yi Xue Za Zhi* 2016; 96: 2059–2063.
13. Seppälä I, Kleber ME, Bevan S, et al. Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. *Sci Rep* 2016; 6: 23207.
14. Allende M, Molina E, Guruceaga E, et al. Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk. *Cardiovasc Res* 2016; 110: 309–318.
15. Smyth GK. limma: Linear Models for Microarray Data. In: Statistics for Biology and Health. pp.397–420.
16. Huang DW, Sherman BT and Lempicki RA. Systematic and integrative analysis of large
gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009; 4: 44–57.

17. Huang DW, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009; 37: 1–13.

18. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 2011; 39: D561–D568.

19. Fan Y, Siklenka K, Arora SK, et al. miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. *Nucleic Acids Res* 2016; 44: W135–W141.

20. Saito R, Smoot ME, Ono K, et al. A travel guide to Cytoscape plugins. *Nat Methods* 2012; 9: 1069–1076.

21. Wang J, Zhong J, Chen G, et al. ClusterViz: a Cytoscape APP for cluster analysis of biological network. *IEEE/ACM Trans Comput Biol Bioinform* 2015; 12: 815–822.

22. Prystowsky EN, Padanilam BJ and Fogel RI. Treatment of atrial fibrillation. *JAMA* 2015; 313: 1950.

23. Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Circulation* 2014; 130: 1847–1858.

24. Hu YF, Yu-Feng H, Yi-Jen C, et al. Inflammation and the pathogenesis of atrial fibrillation. *Nat Rev Cardiol* 2015; 12: 230–243.

25. Harada M, Van Wagoner DR and Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. *Circ J* 2015; 79: 495–502.

26. Guo Y, Lip GYH and Apostolakis S. Inflammatory biomarkers and atrial fibrillation: potential role of inflammatory pathways in the pathogenesis of atrial fibrillation-induced thromboembolism. *Curr Vasc Pharmacol* 2015; 13: 192–201.

27. Zhang H, Liu L, Hu J, et al. MicroRNA regulatory network revealing the mechanism of inflammation in atrial fibrillation. *Med Sci Monit* 2015; 21: 3505–3513.

28. McManus DD and Freedman JE. MicroRNAs in platelet function and cardiovascular disease. *Nat Rev Cardiol* 2015; 12: 711–717.

29. Llombart V, Garcia-Berrocoso T, Bustamente A, et al. Cardioembolic stroke diagnosis using blood biomarkers. *Curr Cardiol Rev* 2014; 9: 340–352.

30. Bhagavatula MRK. Transcription factor MEF2A mutations in patients with coronary artery disease. *Hum Mol Genet* 2004; 13: 3181–3188.

31. Han Y, Yang Y, Zhang X, et al. Relationship of the CAG repeat polymorphism of the MEF2A gene and coronary artery disease in a Chinese population. *Clin Chem Lab Med* 2007; 45: 987–992.

32. Wang L, Mutation of MEF2A in an inherited disorder with features of coronary artery disease. *Science* 2003; 302: 1578–1581.

33. Liu Y, Niu W, Wu Z, et al. Variants in exon 11 of MEF2A gene and coronary artery disease: evidence from a case-control study, systematic review, and meta-analysis. *PLoS One* 2012; 7: e31406.

34. Wang Q. Advances in the genetic basis of coronary artery disease. *Curr Atheroscler Rep* 2005; 7: 235–241.

35. Suzuki E, Satonaka H, Nishimatsu H, et al. Myocyte enhancer factor 2 mediates vascular inflammation via the p38-dependent pathway. *Circ Res* 2004; 95: 42–49.

36. Schumacher FR, Siew K, Zhang J, et al. Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia. *EMBO Mol Med* 2015; 7: 1285–1306.

37. Silvestri P, Di Russo C, Rigattieri S, et al. MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. *Recent Pat Cardiovasc Drug Discov* 2009; 4: 109–118.

38. Zorio E, Medina P, Rueda J, et al. Insights into the role of microRNAs in cardiac diseases: from biological signalling to...
therapeutic targets. *Cardiovasc Hematol Agents Med Chem* 2009; 7: 82–90.

40. Cai B, Pan Z and Lu Y. The roles of microRNAs in heart diseases: a novel important regulator. *Curr Med Chem* 2010; 17: 407–411.

41. Ikeda S, He A, Kong SW, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. *Mol Cell Biol* 2009; 29: 2193–2204.

42. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 2008; 456: 980–984.

43. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrillation. *Basic Res Cardiol* 2012; 107: 278.

44. Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. *Circ Res* 2013; 113: 322–326.

45. Fang L, Ellims AH, Moore XL, et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. *J Transl Med* 2015; 13: 314.

46. Chang M, Jin W and Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. *Nat Immunol* 2009; 10: 1089–1095.

47. Xiao Y, Jin J, Chang M, et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. *Nat Med* 2013; 19: 595–602.

48. Wang L, Zhao M, Guo C, et al. PDCD4 deficiency aggravates colitis and colitis-associated colorectal cancer via promoting IL-6/STAT3 pathway in mice. *Inflamm Bowel Dis* 2016; 22: 1107–1118.

49. Peacock O, Lee AC, Cameron F, et al. Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. *PLoS One* 2014; 9: e10267.

50. Su Q, Li L, Zhou Y, et al. Induction of myocardial PDCD4 in coronary microembolization-related cardiac dysfunction: evidence from a large-animal study. *Cell Physiol Biochem* 2014; 34: 533–542.

51. Su Q, Li L, Wang J, et al. Mechanism of programmed cell death factor 4/nuclear factor-κB signaling pathway in porcine coronary micro-embolization-induced cardiac dysfunction. *Exp Biol Med* 2015; 240: 1426–1433.

52. Su Q, Li L, Liu Y, et al. Ultrasound-targeted microbubble destruction-mediated microRNA-21 transfection regulated PDCD4/NF-κB/TNF-α pathway to prevent coronary microembolization-induced cardiac dysfunction. *Gene Ther* 2015; 22: 1000–1006.

53. O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci U S A* 2007; 104: 1604–1609.

54. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. *Proc Natl Acad Sci U S A* 2009; 106: 2735–2740.

55. Cremer TJ, Ravneberg DH, Clay CD, et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced proinflammatory cytokine response. *PLoS One* 2009; 4: e8508.

56. Wang P, Hou J, Lin L, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. *J Immunol* 2010; 185: 6226–6233.

57. McCoy CE, Sheedy FJ, Qualls JE, et al. IL-10 inhibits miR-155 induction by toll-like receptors. *J Biol Chem* 2010; 285: 20492–20498.

58. Schulte LN, Westermann AJ and Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. *Nucleic Acids Res* 2013; 41: 542–553.

59. Liu WH, Kang SG, Huang Z, et al. A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. *J Exp Med* 2016; 213: 1901–1919.

60. Thomsen KG, Terp MG, Lund RR, et al. miR-155, identified as anti-metastatic by
global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations. *Oncotarget* 2015; 6: 29224–29239.

61. Zadeh MM, Motamed N, Ranji N, et al. Silibinin-induced apoptosis and downregulation of microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. *J Breast Cancer* 2016; 19: 45–52.

62. Hafez MM, Hassan ZK, Zekri ARN, et al. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. *Asian Pac J Cancer Prev* 2012; 13: 591–598.

63. Wang JG, Meng X, Han J, et al. Differential expressions of miRNAs in patients with nonvalvular atrial fibrillation]. *Zhonghua Yi Xue Za Zhi* 2012; 92: 1816–1819.

64. Choi GH, Ko KH, Kim JO, et al. Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke. *Int J Mol Med* 2016; 38: 345–356.

65. Lopez-Ramirez MA, Wu D, Pryce G, et al. MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. *FASEB J* 2014; 28: 2551–2565.

66. Caballero-Garrido E, Pena-Philippides JC, Lordkipanidze T, et al. In vivo inhibition of miR-155 promotes recovery after experimental mouse stroke. *J Neurosci* 2015; 35: 12446–12464.

67. Wen Y, Zhang X, Dong L, et al. Acetylbritannilactone modulates microRNA-155-mediated inflammatory response in ischemic cerebral tissues. *Mol Med* 2015; 21: 197–209.